Webinar
The State of Joint Clinical Assessments in Europe: Latest Developments and Implications for Manufacturer Strategy
calendar

May 22, 2024

Calendar
clock

11:00am - 12:00pm

(GMT-04:00)

Register

View all IQVIA events

In this webinar, industry leaders will discuss the organizational implications of new evidence needs including the content and timing of evidence needed for access and reimbursement.

Key Takeaways:

  • JCA will apply to new oncology asset submissions beginning in 2025 and across all disease areas by 2030
  • JCA will significantly change the nature and timing of evidence required for HTA submission in Europe
  • JCA will require organizational adaptation
  • Coordination throughout with local teams to optimize local HTA decisions

Speakers:

Matthew Barrett
Principal, Value and Access Strategy Consulting, IQVIA

Akim Ziai
Principal, Value and Access Strategy Consulting, IQVIA

Related solutions

Contact Us